Real-time US stock monitoring with expert analysis and strategic recommendations designed for both beginner and experienced investors seeking consistent returns. Our platform adapts to your knowledge level and provides appropriate support at every step of your investment journey.
This analysis covers the April 24, 2026 announcement that Bristol Myers Squibb (NYSE: BMY) and co-marketing partner Pfizer (NYSE: PFE) will list their top-selling anticoagulant Eliquis on the Mark Cuban Cost Plus Drug Company (MCCPDC) platform starting the following week, priced at $345 for a 30-day
Bristol Myers Squibb (BMY) - Partners With Pfizer to List Blockbuster Anticoagulant Eliquis on Mark Cuban Cost Plus Platform at $345 Monthly - Analyst Ratings
BMY - Stock Analysis
4957 Comments
1867 Likes
1
Josbel
Consistent User
2 hours ago
I don’t get it, but I feel included.
👍 218
Reply
2
Thao
Legendary User
5 hours ago
Expert US stock analyst coverage consensus and rating distribution analysis to understand market sentiment. We aggregate analyst opinions to provide a consensus view of Wall Street expectations for any stock.
👍 126
Reply
3
Curtis
Engaged Reader
1 day ago
Early gains are met with minor profit-taking pressure.
👍 77
Reply
4
Laryan
Daily Reader
1 day ago
Exceptional results, well done!
👍 265
Reply
5
Delaya
Insight Reader
2 days ago
I’m pretty sure that deserves fireworks. 🎆
👍 158
Reply
© 2026 Market Analysis. All data is for informational purposes only.